Amarantus Bioscience Holdings Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: Edison Investment Research
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Amarantus Biosciences Inc Announces Chairman Change-Form 8-K
Amarantus Biosciences Inc reported in its Form 8-K that effective July 31, 2012, Martin D. Cleary resigned from his position as a Director and the Chairman of Board of Directors. Also effective July 31, 2012, Eugene Mancino resigned from his position as a Director.
Latest Developments for Amarantus Bioscience Holdings Inc
- Amarantus BioScience Holdings Inc closes warrant solicitation and enters into $20 mln purchase agreement with Lincoln Park Capital Fund, LLC
- Amarantus Bioscience Holdings Inc announcs positive clinical data for Eltoprazine in Phase 2a clinical study Adult Attention Deficit Hyperactivity Disorder
- Amarantus Bioscience Holdings Inc Announces Positive Analytical Performance Data for LymPro Test For Alzheimer's Disease
- Amarantus Bioscience Holdings Inc Announces Positive Orphan Data For MANF In Retinitis Pigmentosa
Latest Key Developments in Biotechnology
- Share this
- Digg this